REFERENCES
  1. Michniacki TF, Ebens CL, Choi SW. Immune-mediated cytopenias after hematopoietic cell transplantation: pathophysiology, clinical manifestations, diagnosis, and treatment strategies. Curr Oncol Rep . 2019;21:87.
  2. Gupta AO, Boelensbe JJ, Ebens CL, et al. Consensus opinion on immune-mediated cytopenias after hematopoietic cell transplant for inherited metabolic disorders. Bone Marrow Transplant . 2021;56:1238-1247.
  3. Faraci M, Zecca M, Pillon M, et al. Autoimmune hematological diseases after allogeneic hematopoietic stem cell transplantation in children: an Italian multicenter experience. Biol Blood Marrow Transplant . 2014;20:272-278.
  4. Driouk L, Schmitt R, Peters A, et al. Daratumumab therapy for post-HSCT immune-mediated cytopenia: experiences from two pediatric cases and review of literature. Mol Cell Pediatr . 2021;8:5.
  5. Canales-Herrerias P, cricks E, Broketa M, et al. High-affinity autoreactive plasma cells disseminate through multiple organs in patients with immune thrombocytopenic purpura. J Clin Invest . 2022;132:e153580.
  6. Kruizinga MD, van Tol MJD, Bekker V, et al. Risk factors, treatment, and immune dysregulation in autoimmune cytopenia after allogeneic hematopoietic stem cell transplantation in pediatric patients.Biol Blood Marrow Transplant . 2018;24:772–778.